Cardiac Arrest News and Research

Latest Cardiac Arrest News and Research

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.

28 Jul 2010

Scientists discover mechanism behind flushing reaction caused by nicotinic acid treatment

Cholesterol influences the health of our hearts and blood vessels. Conventional treatment attempts to reduce the level of "bad" cholesterol, LDL cholesterol, in the blood plasma. The opposite approach, which involves increasing the concentration of "good" HDL cholesterol using nicotinic acid, has proven unpopular among patients up to now. The reason for this is that treatment with nicotinic acid has an unpleasant but harmless side-effect: the drug makes patients turn quite red in the face. Scientists at the Max Planck Institute for Heart and Lung Research in Bad Nauheim have now discovered the mechanism behind this effect, which is known as flushing. This will enable the development of flush inhibitors and thereby the more effective prevention of cardiovascular diseases.

27 Jul 2010

Taiho Pharmaceutical receives approval to market ABRAXANE IV Infusion 100 mg in Japan

Abraxis BioScience, Inc., a fully integrated, global biotechnology company, today announced that Taiho Pharmaceutical Co., Ltd. has received approval from the Ministry of Health, Labor and Welfare to market ABRAXANE IV Infusion 100 mg, Paclitaxel Injection (Suspension with Albumin), for use in the treatment of breast cancer. The New Drug Application (J-NDA) for ABRAXANE was filed with the Ministry of Health, Labor and Welfare in 2008.

23 Jul 2010

Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events

A Phase 3 open-label study, recently published online by Pain Practice, has compared tapentadol extended release tablets, an investigational pain medication, to an existing prescription pain medication, oxycodone controlled release tablets.

20 Jul 2010

Winner of Sudden Cardiac Arrest Foundation's You Can Save a Life Video Awareness Contest announced

The Sudden Cardiac Arrest Foundation today announced the grand prize winner of its You Can Save a Life Video Awareness Contest. The student competition invited teams to submit videos about the impact of sudden cardiac arrest and the importance of CPR and automated external defibrillators, empowering students and communities to make a difference in helping to save lives.

9 Jul 2010

Cedars-Sinai Heart Institute awarded grant to develop new system to predict sudden cardiac arrest

The Cedars-Sinai Heart Institute has been awarded a $1.66 million, four-year grant from the National Heart, Lung and Blood Institute of the National Institutes of Health to develop a measurement system that could help doctors predict which patients could be struck by sudden cardiac arrest, a heart rhythm disturbance that causes instant death in more than 95 percent of cases.

7 Jul 2010

Cambridge Heart commences enrollment in study to identify ischemia in patients with coronary artery disease

Cambridge Heart, Inc., today announced the first patient enrollments in the MTWA-CAD study (Evaluation of Microvolt T-Wave Alternans Testing for the Detection of Active Ischemia in Patients with Known or Suspected Coronary Artery Disease).

7 Jul 2010

Physio-Control initiates field correction on certain LIFEPAK 20/20e defibrillator/monitors

Physio-Control, Inc., a wholly owned subsidiary of Medtronic, Inc.,, announced the company's recent initiation of a field correction on certain LIFEPAK 20/20e defibrillator/monitors manufactured prior to January 9, 2009. Analysis conducted by Physio-Control verified a possible battery (DC) power malfunction on the affected devices. In the malfunction scenario, a loss of battery power may occur while the unit is in operation.

3 Jul 2010

Cambridge Heart announces CMS reimbursement modification for MTWA test

Cambridge Heart, Inc., today announced that effective July 1, 2010, the Centers for Medicare and Medicaid Services (CMS) will allow full reimbursement for both a Microvolt T-Wave Alternans (MTWA) test and a stress test when both tests are performed during the same patient visit. The CMS update removes a previous restriction that substantially limited reimbursement when a patient underwent an MTWA test on the same day as the patient underwent a standard cardiac stress test, echocardiography stress test, nuclear cardiac stress test, or pulmonary stress test.

2 Jul 2010

Saint Thomas Chest Pain Network awarded HRSA grant for placement of AEDs in 14 rural communities

The Saint Thomas Chest Pain Network, a network service provided by Saint Thomas Health Services, was recently awarded a $100,000 Health Resources and Services Administration grant from the United States Department of Health and Human Services for the placement of full-rescue Automated External Defibrillators in 14 rural communities throughout the network.

28 Jun 2010

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Merck today announced that the U.S. Food and Drug Administration (FDA) has approved DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol, a new fixed-dose combination asthma treatment for patients 12 years of age and older. DULERA is not indicated for the relief of acute bronchospasm. DULERA combines an inhaled corticosteroid (mometasone furoate) with a long-acting beta2-agonist (formoterol fumarate).

24 Jun 2010

Study: Traditional methods for assessing patients after cardiac arrest may underestimate chances for survival

Traditional methods for assessing patients after cardiac arrest may be underestimating their chances for survival and good outcomes, according to a new study by University of Pittsburgh School of Medicine researchers now available online in the journal Resuscitation.

24 Jun 2010

Women who experience early menopause may have cardiovascular disease later in life: Study

Women who experience early menopause appear to have more than twice the risk of having a heart attack, stroke or other cardiovascular disease event later in life than do women who do not go through early menopause, a new study indicates. The results will be presented Saturday at The Endocrine Society's 92nd Annual Meeting in San Diego.

22 Jun 2010

Abraxis BioScience presents phase 3 trial data on metastatic malignant melanoma

Abraxis BioScience, Inc. presented trial design information from its ongoing phase 3 registration trial of nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension), in melanoma, an aggressive form of skin cancer that affects more than 68,000 people in the U.S. each year.

11 Jun 2010

AACN endorses scientific statement on prevention of TdP

The American Association of Critical-Care Nurses recently endorsed "Prevention of Torsades de Pointes in Hospital Settings," a scientific statement from the American Heart Association, Dallas, and American College of Cardiology Foundation, Washington, D.C.

10 Jun 2010

New AAN guideline provides step-by-step process for determining brain death in adults

In an effort to create a uniform and accurate method for determining brain death, the American Academy of Neurology has issued an updated guideline that provides doctors with a step-by-step process for determining brain death in adults. The guideline is published in the June 8, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.

9 Jun 2010

Multiple presentations on nab-driven chemotherapy at 46th ASCO

Abraxis BioScience, Inc. presented abstracts describing 10 trials of nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension), for the treatment of breast cancer at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

9 Jun 2010

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

Abraxis BioScience, Inc. announced today that findings from their phase 3 randomized trial of nanoparticle albumin bound driven chemotherapy, nab-paclitaxel (ABRAXANE for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) plus carboplatin, showed a statistically significant 31 percent improvement in overall response rate when compared with Taxol (paclitaxel) injection plus carboplatin in the first-line treatment of patients with non-small cell lung cancer.

8 Jun 2010

Arrhythmia Alliance launches 'Know Your Pulse' global awareness campaign on World Heart Rhythm Week

Arrhythmia Alliance, the Heart Rhythm Charity, announced today the results of a survey conducted in Europe that showed a large number of respondents ignore basic measures to check for potential cardiac arrhythmias, or heart rhythm disorders. To raise awareness of the importance of pulse checking and to inform people about how to take their pulse, the Arrhythmia Alliance will open 2010 World Heart Rhythm Week (7-13 June) with the launch of the global awareness campaign 'Know Your Pulse'.

7 Jun 2010

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.

4 Jun 2010

Cardiac Arrest News and Research

Latest Cardiac Arrest News and Research

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Scientists discover mechanism behind flushing reaction caused by nicotinic acid treatment

Taiho Pharmaceutical receives approval to market ABRAXANE IV Infusion 100 mg in Japan

Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events

Winner of Sudden Cardiac Arrest Foundation's You Can Save a Life Video Awareness Contest announced

Cedars-Sinai Heart Institute awarded grant to develop new system to predict sudden cardiac arrest

Cambridge Heart commences enrollment in study to identify ischemia in patients with coronary artery disease

Physio-Control initiates field correction on certain LIFEPAK 20/20e defibrillator/monitors

Cambridge Heart announces CMS reimbursement modification for MTWA test

Saint Thomas Chest Pain Network awarded HRSA grant for placement of AEDs in 14 rural communities

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Study: Traditional methods for assessing patients after cardiac arrest may underestimate chances for survival

Women who experience early menopause may have cardiovascular disease later in life: Study

Abraxis BioScience presents phase 3 trial data on metastatic malignant melanoma

AACN endorses scientific statement on prevention of TdP

New AAN guideline provides step-by-step process for determining brain death in adults

Multiple presentations on nab-driven chemotherapy at 46th ASCO

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

Arrhythmia Alliance launches 'Know Your Pulse' global awareness campaign on World Heart Rhythm Week

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Cardiac Arrest News and Research

Latest Cardiac Arrest News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in